Multiple myeloma
Conditions
Interventions
None listed
Sponsors
Kyoto University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. A 20 to 80 year-old patient who was diagnosed with multiple myeloma according to the diagnostic criteria of the Hematologic Malignancy Practice Guideline published by the Japanese Society of Hematology. 2. A patient who was judged as ineligible for both autologous and allogeneic hematopoietic cell transplantation by the attending physician. 3. A patient who has measurable M-protein in serum or urine. 4. A patient who agreed with the registration for RevMate and can keep its administrative procedures. 5. A newly diagnosed myeloma patient who will be treated with lenalidemide and dexamethasone (Ld) as the first-line treatment, or a relapsed or refractory myeloma patient who will be treated with a combination of Ld and elotuzumab (ELd) or daratumumab (DLd). 6. A patient who provided written informed consent for this study.
Exclusion criteria
Exclusion criteria: A patient who is judged to be inappropriate to participate in this study by the attending physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best therapeutic effect | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunological parameters, progression-free survival, overall survival, time to next treatment, safety | — |
Countries
Japan
Contacts
Public ContactToshio Kitawaki
Kyoto University Hospital Department of Hematology and Oncology
Outcome results
None listed